Adalimumab
- Atc Codes:L04AB04
- CAS Codes:331731-18-1
- PHARMGKB ID:331731-18-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Humira; Belgium: Humira; Bulgaria: Humira; Cyprus: Humira; Czech Republic: Humira; Denmark: Humira; Estonia: Humira; Finland: Humira; France: Humira; Germany: Humira; Greece: Humira; Hungary: Humira; Ireland: Humira; Italy: Humira; Latvia: Humira; Lithuania: Humira; Luxembourg: Humira; Malta: Humira; Netherlands: Humira; Poland: Humira; Portugal: Humira; Romania: Humira; Slovakia: Humira; Slovenia: Humira; Spain: Humira; Sweden: Humira; UK: Humira.
North America
Canada: Humira; USA: Humira.
Latin America
Argentina: Humira; Brazil: Humira; Mexico: Humira.
Asia
Japan: Humira.
Drug combinations
Chemistry
Adalimumab: Mw: approx. 148000.01. Immunoglobulin G~1~, anti-(human tumor necrosis factor)(human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer. CAS-331731-18-1 (2002).
Pharmacologic Category
GI Drugs, Miscellaneous. Disease-modifying Antirheumatic Drugs. Immunosuppressants; Tumor Necrosis Factor Inhibitors; Monoclonal Antibody. (ATC-Code: L04AB04).
Mechanism of action
Recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF), interfering with cytokine-driven inflammatory processes.
Therapeutic use
Treatment of active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, plaque psoriasis, or juvenile idiopathic arthritis.
Pregnancy and lactiation implications
Use during pregnancy only if clearly needed. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to adalimumab or any component of the formulation. Severe infection (e.g. sepsis, tuberculosis, opportunistic infection).
Warnings and precautions
Anaphylaxis/hypersensitivity reactions (rarely). Rare cases of autoimmune disorder (including lupus-like syndrome) have occurred. Fatal infections (tuberculosis, invasive fungal, other opportunistic infections) may develop. Reactivation of hepatitis B virus (rarely). May affect defenses against malignancies. Pancytopenia (including aplastic anemia)(rarely). Tuberculosis (disseminated or extrapulmonary) reactivation. Caution in pre-existing or recent onset CNS demyelinating disorders and in heart failure or decreased left ventricular function. Avoid live vaccines concurrently.